Evernow Alternatives: Best Options for Every Menopause Use Case

Is Evernow Legit? What They Actually Prescribe

Evernow operates as a licensed telehealth company prescribing FDA-approved hormone therapy for menopause symptoms. The platform is not a scam. It connects patients with board-certified clinicians who evaluate symptom questionnaires and prescribe standard HRT formulations: transdermal estradiol (patches or gel), oral micronized progesterone (Prometrium or generic), and vaginal estrogen creams or inserts.

The 2022 North American Menopause Society (NAMS) Position Statement confirms that hormone therapy remains the most effective treatment for vasomotor symptoms and genitourinary syndrome of menopause [1]. Evernow's prescribing aligns with these guidelines. Their formulary sticks to a conservative selection of FDA-approved products, which is appropriate for straightforward cases but may limit options for women who need testosterone, DHEA, or combination therapies.

One drawback: Evernow relies heavily on asynchronous messaging rather than video visits. For women with complex medical histories (prior VTE, breast cancer family history, liver disease), a synchronous clinical evaluation provides better risk stratification. The 2017 Endocrine Society Clinical Practice Guideline on menopausal HRT recommends individualized risk assessment before initiating therapy [3].

How Evernow Compares on Cost

The baseline Evernow pricing structure runs $149 for the initial consultation and $49 per month for ongoing care, with medications billed separately through a partnered pharmacy. Annual out-of-pocket cost (excluding medications) totals roughly $737.

This positions Evernow in the mid-to-upper range of menopause telehealth pricing. For women without insurance coverage for HRT consultations, cheaper alternatives exist. For women whose insurance covers specialist visits, a traditional menopause-certified provider (NAMS-certified clinician directory available at menopause.org) may cost only a specialist copay.

A 2023 analysis in Menopause found that direct-to-consumer telehealth platforms charged 30% to 200% more than insurance-based equivalents for identical HRT regimens, though they offered faster access (median 3 days vs. 28 days to first prescription) [4]. Speed matters when hot flashes disrupt sleep nightly.

Alternative 1: Midi Health (Best for Complex Cases)

Midi Health employs OB/GYNs, endocrinologists, psychiatrists, and registered dietitians on a single platform focused exclusively on midlife women's health. Their model uses synchronous video visits rather than asynchronous questionnaires.

For women with comorbidities (obesity, diabetes, mood disorders, thyroid disease co-occurring with menopause), Midi's multi-specialty team offers clinical depth Evernow cannot match. They prescribe the full range of FDA-approved HRT plus off-label options like low-dose gabapentin for hot flashes in women who cannot take estrogen.

The WHI follow-up data published in JAMA (2017) demonstrated that the risk-benefit calculus of HRT differs substantially by age, years since menopause, and baseline cardiovascular risk [5]. A platform with specialist oversight can better manage these variables. Midi accepts some insurance plans, potentially reducing cost below Evernow's cash-pay model.

Alternative 2: Alloy (Best for Budget-Conscious Patients)

Alloy eliminates the subscription fee model entirely. Consultations are included with product purchases, and their estradiol patch + progesterone capsule combination starts around $85 per month all-in.

The trade-off is clinical contact. Alloy's physician interactions are minimal after initial prescribing. For a woman with textbook vasomotor symptoms, no contraindications, and a straightforward menopause presentation, this streamlined approach works. For anyone needing dose titration, symptom layering management, or careful monitoring, the light-touch model may underserve.

Alloy's formulary includes vaginal estrogen (estradiol cream), oral progesterone, and transdermal estradiol. They do not prescribe testosterone, compounded preparations, or non-hormonal prescription alternatives like paroxetine 7.5 mg (Brisdelle), which the FDA approved specifically for hot flashes in women who cannot or prefer not to use hormones [6].

Alternative 3: Winona (Best for Compounded and Bioidentical Options)

Winona differentiates by offering compounded bioidentical hormone preparations alongside FDA-approved options. Their pharmacy compounds custom-dose estradiol and progesterone creams, which some women prefer for dose flexibility.

A critical distinction: "bioidentical" does not mean "compounded." FDA-approved estradiol patches and micronized progesterone capsules are chemically bioidentical to endogenous hormones. The 2020 AACE/ACE Position Statement emphasizes that FDA-approved bioidentical formulations should be preferred over compounded versions because they undergo rigorous quality testing [7].

Winona's pricing runs $89 to $199 per month depending on formulation complexity. Their model suits women who want precise dose customization or who have failed standard commercial products at available strengths. Women who respond well to standard 0.05 mg/day estradiol patches gain no advantage from compounding.

Alternative 4: HealthRX (Best for Broad Formulary and Testosterone Access)

HealthRX provides menopause HRT alongside testosterone therapy, peptide protocols, and metabolic health management. This breadth matters because testosterone deficiency contributes to reduced libido, fatigue, and sarcopenia in postmenopausal women.

The 2019 Global Consensus Position Statement on testosterone therapy for women concluded that testosterone (at physiologic female doses) can be prescribed for hypoactive sexual desire disorder in postmenopausal women when other causes have been excluded [8]. Neither Evernow nor most menopause-focused telehealth platforms prescribe testosterone.

HealthRX also provides access to GLP-1 receptor agonists for women experiencing menopause-associated weight gain. A post-hoc analysis of the STEP trials showed that semaglutide 2.4 mg produced 14.9% mean body weight reduction at 68 weeks (N=1,961) regardless of menopausal status [9]. For women whose primary complaint is metabolic deterioration during the menopause transition, a platform offering both HRT and metabolic pharmacotherapy covers more clinical ground.

Alternative 5: Traditional NAMS-Certified Clinician (Best for Insurance Coverage)

The North American Menopause Society maintains a practitioner directory of clinicians who have passed the NAMS competency examination. These providers accept insurance, perform in-person examinations, and can order imaging and labs directly.

For women with FSH-confirmed menopause, established PCP relationships, and insurance that covers specialist visits, a NAMS-certified clinician remains the gold standard. Wait times average 4 to 8 weeks for new patients. The tradeoff against telehealth platforms is access speed, not quality.

Dr. Stephanie Faubion, NAMS Medical Director, stated in 2022: "Only about 20% of OB/GYN residency programs provide menopause-specific training, which is why certification matters for this population" [10]. Choosing a NAMS-certified provider ensures menopause-specific competency that general telehealth platforms cannot guarantee.

Non-Hormonal Alternatives Worth Considering

Not every woman with menopause symptoms needs or wants HRT. The 2023 Cochrane review on non-hormonal interventions for hot flashes identified several evidence-based options [11]:

Fezolinetant (Veozah): FDA-approved in 2023 as the first neurokinin-3 receptor antagonist for vasomotor symptoms. In the SKYLIGHT trials, fezolinetant 45 mg reduced moderate-to-severe hot flash frequency by 61.3% at 12 weeks vs. 42.4% for placebo (P<0.001) [12]. No hormonal mechanism. Available through most telehealth platforms including HealthRX.

Paroxetine 7.5 mg (Brisdelle): The only SSRI with a specific FDA indication for hot flashes. Reduces frequency by approximately 33% over placebo in clinical trials [6]. Appropriate for women with breast cancer history or estrogen contraindications.

Cognitive Behavioral Therapy for menopause (CBT-Meno): The MENOS 2 trial (N=140) showed group CBT reduced hot flash interference scores by 50% at 6 weeks, maintained at 26 weeks [13]. Addresses the distress component rather than frequency.

Stellate ganglion block: Emerging evidence suggests this interventional procedure reduces hot flash frequency in women who cannot take systemic therapy. A 2021 pilot study in Menopause (N=40) showed 52% reduction in hot flash frequency at 6 months post-procedure [14].

When to Choose Evernow vs. an Alternative

The decision framework depends on three variables: symptom complexity, insurance status, and formulary needs.

Choose Evernow if you have straightforward vasomotor symptoms, no significant comorbidities, prefer asynchronous care, and accept cash-pay pricing for the convenience of rapid access (typically within 48 hours of questionnaire completion).

Choose Midi Health if you have co-occurring mood disorders, thyroid dysfunction, metabolic syndrome, or a personal/family history requiring careful HRT risk stratification.

Choose Alloy if cost is your primary concern and you have an uncomplicated symptom profile with no contraindications to standard-dose HRT.

Choose HealthRX if you need testosterone for HSDD, want GLP-1 access for metabolic concerns, or prefer a platform that addresses menopause within a broader hormonal optimization framework.

Choose a NAMS-certified clinician if you have insurance coverage, prefer in-person care, need procedural interventions, or have contraindications requiring detailed physical examination.

The Perimenopause Gap: Where Most Platforms Fall Short

Perimenopause presents a diagnostic challenge that asynchronous telehealth handles poorly. Hormone levels fluctuate wildly during this transition. A single FSH draw means little. The 2012 STRAW+10 staging system defines perimenopause by menstrual cycle variability (7+ day change in cycle length) rather than laboratory values [15].

Women in early perimenopause may experience symptoms while still having "normal" hormone levels. Evernow and similar platforms that gate prescribing on questionnaire algorithms may miss these patients or inappropriately apply postmenopausal dosing protocols.

Dr. Mary Claire Haver, author of The New Menopause, noted in 2024: "The average woman sees three providers over four years before receiving a perimenopause diagnosis. Telehealth can shorten this timeline, but only if the platform's clinical algorithms account for the STRAW+10 staging criteria rather than relying on age and symptom checklists alone."

Platforms with synchronous physician visits and serial lab monitoring (Midi Health, HealthRX, NAMS-certified clinicians) better serve perimenopausal patients whose presentations are ambiguous.

Safety Monitoring: What Good Menopause Care Requires

The 2022 NAMS Position Statement recommends annual reassessment of HRT with consideration of ongoing benefits versus risks [1]. Minimum monitoring includes:

• Annual mammography (no change from baseline screening)
• Endometrial evaluation if unexpected bleeding occurs on HRT
• Lipid panel at baseline and 3 months (oral estrogen raises triglycerides)
• Blood pressure monitoring (transdermal estradiol is preferred for hypertensive women)
• Bone density screening per USPSTF guidelines (all women 65+, younger women with risk factors)

Evernow provides medication management but does not coordinate imaging, lab orders, or procedural follow-up. Women using any telehealth-only platform should maintain a parallel relationship with a local provider for hands-on monitoring. This is not optional. It is guideline-concordant care.

The Women's Health Initiative demonstrated that combined estrogen-progestin therapy increased breast cancer risk by 26% (HR 1.26 to 95% CI 1.00-1.59) after 5.6 years of use [16]. Ongoing surveillance is the clinical standard that makes long-term HRT safe.